Loading stock data…
$3.44-0.03 (-0.86%)
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Aclaris Therapeutics, Inc. in the Healthcare sector is trading at $3.44 with a market capitalization of $876M. Wall Street consensus targets $10.18 (11 analysts), implying a +196.0% move over the next 12 months. The stock is currently 48% below its 52-week high of $6.60, remaining 23.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.63M↓ | $2.00M↑ | $1.29M↓ | $3.30M↑ | $1.78M |
| Gross Profit | $176,000↓ | $208,000↑ | -$174,000↓ | $850,000↑ | -$73,000 |
| Operating Income | -$23.94M↓ | -$22.19M↑ | -$22.33M↓ | -$17.05M↓ | -$16.91M |
| Net Income | -$21.50M↓ | -$19.82M↓ | -$19.80M↓ | -$14.61M↑ | -$15.43M |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug...